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The endocannabinoid system (ECS) and reactive oxygen species (ROS) consti-
tute two key cellular signalling systems that participate in the modulation of
diverse cellular functions. Importantly, growing evidence suggests that
cross-talk between these two prominent signalling systems acts to modulate
functionality of the ECS as well as redox homeostasis in different cell types.
Herein, we review and discuss evidence pertaining to ECS-induced regulation
of ROS generating and scavenging mechanisms, as well as highlighting emer-
ging work that supports redox modulation of ECS function. Functionally, the
studies outlined reveal that interactions between the ECS and ROS signalling
systems can be both stimulatory and inhibitory in nature, depending on cell
stimulus, the source of ROS species and cell context. Importantly, such
cross-talk may act to maintain cell function, whereas abnormalities in either
system may propagate and undermine the stability of both systems, thereby
contributing to various pathologies associated with their dysregulation.
1. Introduction
The cellular redox environment constitutes a delicate balance between the pro-
duction of reactive oxygen species (ROS) and their removal by antioxidant
enzymes and small-molecular-weight antioxidants. At low concentrations,
ROS are involved in regulating numerous physiological events, including
their ability to mediate signal transduction from membrane receptors, thereby
facilitating the activation of multiple proteins and enzymes [1,2]. However,
excess accumulation of intracellular ROS causes oxidative stress, which can
damage cellular membranes, promote mitochondrial injury and induce cell
death, thereby negatively impacting upon cell function and survival [3–5].
Notably, this is largely owing to the damaging effects that free radicals
convey upon cellular lipids, proteins and DNA, thus impairing their normal
function. Accordingly, the dysregulation of redox homeostasis has been
linked with the development of various pathologies, including those associated
with metabolic disorders such as type 2 diabetes and obesity, cardiovascular
disease, as well as various neurodegenerative disorders (e.g. Alzheimer’s
disease, Parkinson’s disease and multiple sclerosis; figure 1) [6–11]. Conse-
quently, there is growing interest in identifying cellular pathways and/or
processes that can regulate ROS levels, for example by altering the balance
between pro-oxidants and free radical scavenging molecules. In this review,
we explore experimental evidence supporting a role for the endocannabinoid
system (ECS) in the modulation of redox homeostasis and provide examples
of how this relationship may impact upon cellular function.
2. Reactive oxygen species: generation and
neutralization
ROS are oxygen-containing molecules that are highly reactive in redox reac-
tions, and are primarily produced by two metabolic sources: the
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mitochondrial electron-transport chain, and/or through
oxygen-metabolizing enzymatic reactions such as those cata-
lysed by xanthine oxidases, the cytochrome P450 system,
NADPH oxidases, myeloperoxidase, lipoxygenase and nitric
oxide synthase [12–16] (figure 2). Oxygen concentrations
can also act as a key determinant of ROS production.
Indeed, molecular oxygen is the terminal electron acceptor
during energy production whereby it accepts an additional
electron to create superoxide (.O2
2), a highly reactive form
of oxygen. Notably, the superoxide anion can act as a precur-
sor for the formation of other ROS moieties including
peroxynitrite (ONOO2), and hydroxyl radicals (.OH) through
its reaction with transition metals (e.g. cuprous and ferrous
ions; figure 2).
Importantly, there is substantial evidence supporting a
role for ROS as key signalling intermediates that can regu-
late numerous cellular processes, including cell growth and
proliferation, by modulating a number of different pro-
tein kinases and ion channels [10,17–20]. Cellular ROS
levels are maintained by controlling the production and
neutralization of ROS by various antioxidant enzymes and
small-molecular-weight antioxidants. For example, super-
oxide is converted to hydrogen peroxide by members of
the superoxide dismutase (SOD) family of enzymes, includ-
ing manganese-dependent SOD (MnSOD), copper/zinc-
dependent SOD (CuZnSOD) and extracellular SOD (EcSOD).
MnSOD is a mitochondrial enzyme that functions to neutral-
ize ROS generated by these organelles [21]. In contrast,
CuZnSOD resides within both the cytoplasm and nucleus,
while EcSOD is present in the plasma membrane and extra-
cellular space [22]. Two other key antioxidant enzymes
include catalase and glutathione peroxidase (GPx), which
act to neutralize H2O2 by catalysing its conversion to water.
Different isozymes of GPx are present in most subcellular
compartments, and function to convert reduced monomeric
glutathione (GSH; g-L-glutamyl-L-cysteinyl-glycine) into its
oxidized form (GSSG; glutathione disulfide) using hydrogen
peroxide as a substrate, whereas catalase is found primarily
in peroxisomes [23–25]. In the case of glutathione, its cysteine
residue forms a redox-active thiol group which becomes
oxidized when GSH reduces target molecules [26].
Additional intracellular small-molecular-weight antioxidants
include cysteine, vitamin C (ascorbic acid) and vitamin E
(a-tocopherol). Alternatively, chemical antioxidants such as
N-acetyl-L-cysteine are also widely used as ROS scavengers.
3. The endocannabinoid system
The ECS is a ubiquitous ligand-directed signalling system
that has been implicated in regulating a wide range of
physiological processes and pathologies, including energy
homeostasis, cardiovascular disease, cancer and neurodegen-
eration [27–30]. Two key lipid-derived molecules that act as
endogenous ligands for this system are anandamide (N-ara-
chidonoylethanolamine (AEA)) and 2-arachidonoylglycerol
(2-AG)—commonly referred to as endocannabinoids. Both
AEA and 2-AG can be synthesized on demand within
the plasma membrane from arachidonic acid-derived
lipids [31,32]. Anandamide generation from its membrane
phospholipid precursor N-acylphosphatidylethanolamine
(NAPE) is driven by the action of the enzyme NAPE-
hydrolysing phospholipase D (NAPE-PLD) [33]. In contrast,
phospholipase C-mediated cleavage of membrane phospha-
tidylinositols gives rise to a diacylglycerol precursor whose
subsequent hydrolysis (via diacylglycerol lipase activity) per-
mits the formation of 2-AG [34]. In addition to these synthetic
pathways, enzymes that catalyse the degradation of ananda-
mide and 2-AG have also been characterized, including fatty
acid amide hydroxylase (FAAH) and monoacylglycerol
lipase (MAGL), respectively [35].
Both AEA and 2-AG evoke cellular and physiological
responses through binding and activating two distinct G
protein-coupled receptors identified as the cannabinoid
type 1 (CB1R) and type 2 (CB2R) receptors [36–39]. Indeed,
various synthetic CB1R and/or CB2R agonists (e.g.
CP-55,940, ACEA, WIN-55,212-2, JWH-133 and HU-210)
have been used to provide mechanistic insight into the
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Figure 1. ROS involvement in disease pathogenesis. Schematic of the involvement of increased ROS production in the development of various pathologies.
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regulation of cellular processes by the ECS (table 1)
[40,46,47,50,51]. Importantly, these are often applied in combi-
nation with selective receptor antagonists to determine
receptor-specific responses. Such cannabinoid receptor block-
ers act either by competitively binding and preventing
activation of a receptor by an agonist (i.e. as an antagonist),
and/or function as inverse agonists through suppressing spon-
taneous (ligand-free) receptor signalling. For example,
SR141716 (also known as rimonabant) has been shown to act
as both a CB1R antagonist and an inverse agonist (table 1)
[52,53]. Notably, endocannabinoids have also been reported
to mediate some of their biological effects through alternative
molecular targets such as the orphan G protein-coupled recep-
tor GPR55, the transient receptor potential cation channel
(TRPV1), as well as the peroxisome proliferator-activated
receptor (PPAR) alpha and gamma isoforms [54–56].
4. Endocannabinoid system-mediated
regulation of reactive oxygen species
There is accumulating evidence that supports a key role for
the ECS in the modulation of ROS production in different
cell types. For example, extensive work carried out investi-
gating the neuroprotective properties of cannabinoid
ligands has revealed a crucial link between the ECS and
redox homeostasis [57–60]. For example, anandamide has
been reported to attenuate neurotoxicity in response to oxi-
dative stress [58,61]. In accord with this, the mixed CB1R/
CB2R agonistWIN-55,212-2 and the plant-derived cannabinoid
tetrahydrocannabinol (THC) have both been shown to protect
serum-deprived astrocytes against H2O2-induced apoptosis
[57]. Notably, this protective action was found to be prevented
by the selectiveCB1Rblocker SR141716, suggesting the involve-
ment of CB1R in mediating these anti-apoptotic and/or
antioxidant actions. However, it is noteworthy that the protec-
tive effect of THC may be cell specific as judged by the finding
that activation of CB1R by THC increases cellular susceptibility
of C6 glioblastoma cells to oxidative damage [62].
Notably, as well as responses mediated through CB1R,
there is evidence to suggest that stimulation of CB2R may
also convey beneficial free radical scavenging effects. Indeed,
in a study by Ribeiro et al. [60], and co-workers, the selective
CB2R agonist AM1241 was shown to almost completely
block ROS generation in response to lipopolysaccharide
(LPS) in BV-2 cells. Consistent with this, CB2R activation has
also been reported to attenuate oxidative stress damage in var-
ious tissue types, including brain [59], kidney [63], heart [64]
and liver [65]. Moreover, previous work using CB2R agonists
and/or knockout mice indicates that activation of CB2R con-
fers protection against hepatic ischaemia–reperfusion (I/R)
injury, concomitant with its ability to alleviate tissue free rad-
ical damage [66–68]. Allied to this, further evidence
supporting a protective role for the ECS was provided in a
study by Cao et al. [65], who demonstrated that pharmacologi-
cal inhibition of monoacylglycerol lipase, the enzyme which
catalyses the hydrolysis of 2-AG, led to the suppression of oxi-
dative stress and associated inflammation in liver tissue
following hepatic I/R injury in mice [65]. Notably, the protec-
tive effects of MAGL inhibition against hepatic I/R injury
involved increased endocannabinoid signalling via CB2R [65].
Conversely, stimulation of the ECS has also been demon-
strated to induce the production of ROS in certain cell types
[69–71]. For example, 2-AG stimulation has been shown to
promote an increase in cellular ROS in BeWo trophoblasts
[71]. Moreover, increased ROS and concomitant TNF-a cyto-
kine production have been reported in human macrophages
following CB1R activation, with both responses being attenu-
ated by pharmacological inhibition of CB1R [69]. Moreover,
CB1R inhibition using SR141716 has been found to
ameliorate diabetes-induced retinal oxidative stress and
inflammation, as well as improving oxidative stress in mice
with non-alcoholic fatty liver disease [72]. In accord with
this, evidence from a number of studies indicates that CB1R
stimulation can either promote and/or facilitate oxidative
stress and associated inflammation and/or cell death in
human coronary artery endothelial cells [70], as well as in
various models of cardiomyopathy [28,73,74], and nephropa-
thy [75]. In addition, work by Dando et al. [76] showed that
activation of CB1R or CB2R promotes oxidative stress in
Panc1 pancreatic cancer cells resulting in the AMP-activated
protein kinase (AMPK)-dependent induction of autophagy,
which may, at least in part, account for the observed inhibi-
tory effects of cannabinoid receptor ligands upon tumour
cell growth [77–79]. Importantly, such findings are often
supported by data demonstrating the beneficial effects on
ROS-related inflammation and/or cell death following
genetic deletion or pharmacological inhibition of CB1R
[72,74,75,77,78].
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Figure 2. Summary of pathways involved in ROS production and clearance.
Pathological conditions such as chronic inflammation, cardiovascular disease
(CVD), as well as obesity and diabetes can lead to the aberrant production
of various oxygen radicals from molecular oxygen, including superoxide (O2
2),
peroxides and hydroxyl radicals. A number of different enzymes have been
implicated in mediating this process including NADPH oxidase (NOX),
xanthine oxidase (XO), cyclooxygenase (COX), lipoxygenase (LPX), nitric
oxide synthase (NOS) and cytochrome P450 isoforms as well as ROS derived
from mitochondria (Mito). In response, cells will often initiate an antioxidant
response that facilitates the neutralization of ROS into less harmful products
by activating enzymes such as superoxide dismutase (SOD), catalase and glu-
tathione peroxidase, in an attempt to alleviate the damaging effects of ROS
upon lipid, protein and DNA integrity.
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Intriguingly, CB1R and CB2R have also been reported to
differentially regulate ROS production within the same cell
type. For example, a study by Han et al. [69] demonstrated
that CB1R activation led to the upregulation of ROS levels
in RAW264.7 macrophages, whereas CB2R stimulation in
the same cells acted to suppress CB1R-stimulated ROS pro-
duction through a pathway involving the small G protein
Rap1. Therefore, modulation of these distinct cannabinoid
receptors can promote differential responses with respect
to cellular redox homeostasis, even within one specific
cell type.
4.1. Mechanisms underlying cellular reactive oxygen
species production by the endocannabinoid system
It is likely that the ability of the ECS to modulate the pro-
duction of ROS and reactive nitrogen species is largely
mediated through alterations in the expression and/or
activity of enzymes implicated in the generation of these
free radical species. For example, the NADPH oxidase
(Nox) family of proteins are key generators of cellular ROS,
particularly in central nervous system cell types such as
neurons, astrocytes and microglia under pathophysiological
conditions [80,81]. Notably, treatment of H2O2-stimulated
HT22 neuronal cells with AEA led to the suppression of
intracellular ROS and Nox2 protein/mRNA expression,
with these antioxidant responses being reversed by appli-
cation of the CB1R antagonist AM251 or CB1R-siRNA [82].
The authors of the same study also demonstrated that
under conditions of oxidative stress, AEA acted to raise intra-
cellular levels of SOD and GSH, while concomitantly
decreasing GSSG. Importantly, these responses were pre-
vented by AM251, indicating that AEA could restore the
balance of intracellular antioxidants and pro-oxidants
through targeting CB1R. In accord with these findings, treat-
ment of streptozotocin-induced diabetic rats with D9-THC
was also reported to increase pancreatic glutathione levels,
as well as enzymatic activities of SOD and catalase [83]. Con-
versely, in other cell types, CB1R inhibition (by either
pharmacological or genetic silencing) has been shown to
attenuate ROS formation by repressing the expression of
Nox isoforms [28,74,75,84]. Therefore, these findings suggest
that the pathways involved in mediating the effects of canna-
binoid receptor modulation upon ROS formation may be
cell-type-specific. Notably, both CB1R and CB2R agonists
have also been reported to repress the expression/activity
of cyclooxygenase, an enzyme implicated not only in
the generation of ROS but also in the degradation of
anandamide [85–87].
Alternatively, the ability of ECS stimulation to regulate
the production of cellular ROS may be mediated through
the accumulation of toxic lipid intermediates. For example,
activation of CB1R and/or CB2R has been associated with
increased ceramide formation in various cell types (e.g. hep-
atocytes, colon cancer cells) through either increased
sphingomyelin hydrolysis or ceramide de novo synthesis
[88–90]. This is in accord with the reported ability of cera-
mide to stimulate activation of NADPH oxidase by
promoting translocation of its regulatory p47phox subunit to
the plasma membrane [91]. Conversely, chronic CB1R stimu-
lation has also been reported to protect against the sensitizing
effects of ceramide towards H2O2-induced loss of astrocyte
viability [57]. Therefore, some of the biological actions of can-
nabinoid receptor modulation, for example the maintenance
of cell viability, may occur partly as a result of ECS
modulation of ceramide and ROS formation [92].
In addition, various protein kinases may also be impli-
cated in mediating ECS regulation of ROS. One such
candidate is the cyclic AMP-dependent protein kinase A
(PKA), whose regulation of ROS production has been
described in several systems, including leptin-stimulated
endothelial cells [93], tumour necrosis factor-treated fibrosar-
coma cells [94], and in cardiomyocytes following hypoxia
and reoxygenation [95]. Given the fact that PKA has been
implicated in positively regulating the expression and/or
activity of enzymes involved in ROS generation such as
NADPH oxidase and nNOS [96,97], and that activation of
CB1R can lead to reduced cellular levels of cyclic AMP and
the corresponding inhibition of PKA [98], this may, at least
Table 1. Synthetic modulators of cannabinoid receptor function. Citations refer to studies performed using the compounds listed in order to elucidate the
functional role of CB1R and CB2R.
name
activity at CB1
(Ki in nM)
activity at CB2
(Ki in nM) comments references
ACEA 1.4+ 0.3 .2000 selective CB1 receptor agonist [40,41]
AM251 7.5 2000–3000 selective CB1 receptor antagonist/inverse
agonist
[42,43]
SR141716 1.8+ 0.2 — selective CB1 receptor antagonist/inverse
agonist
[44]
JWH-133 680 3.4 selective CB2 receptor agonist [45]
AM630 5.2  103 31.2 selective CB2 receptor antagonist/inverse
agonist
[46]
CP-55940 0.5+ 0.1 2.8+ 0.4 non-selective potent CB1/2 receptor agonist [47]
HU-210 0.1–0.7 0.2–0.5 non-selective potent CB1/2 receptor agonist [48]
WIN-55,212-2 4.4+ 1.3 1.2+ 0.25 non-selective CB1/2 receptor agonist [49]
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in part, act as a means by which CB1R stimulation acts
to suppress ROS formation in certain cell types, such as
neuronal cells [61].
Protein kinase C (PKC) activity may also be involved in
mediating the pro- and/or antioxidant responses induced by
ECS stimulation. Indeed, various PKC isoforms have been
shown to convey biological actions of cannabinoid ligands
[99–101]. Moreover, PKC has been reported to disrupt canna-
binoid actions through its ability to serine phosphorylate the
CB1 receptor [102]. Based on previous findings that PKC iso-
forms (e.g. PKCa and PKC1) can facilitate and/or stimulate
ROS formation, for example through activation ofNADPHoxi-
dase [103,104], it is plausible that ECS-mediated regulation of
ROS homeostasis may also be mediated, at least in part,
through the activity of one or more PKC isoforms, although
further work will be required to determine their involvement.
In addition, active PKC can stimulate the MEK/ERK1/2
signalling pathway whose activation has been shown to upre-
gulate Nox5 activity [105], as well as being positively
modulated by CB1R and/or CB2R activity [30,106–108]. Fur-
thermore, stimulation of RAW264.7 cells by the CB1R agonist
ACEA was found to induce ROS generation by a pathway
dependent upon p38 MAPK, a protein kinase which can also
be stimulated in response to PKC activity [69,109].
Another potential regulator of ROS production by the
ECS is Rap1, a small G protein of the Ras family. In a
study by Han et al. [69], active Rap1 was demonstrated to
inhibit CB1R-induced generation of intracellular ROS and
associated pro-inflammatory responses in murine peritoneal
macrophages. Moreover, expression of a dominant-negative
form of Rap1 profoundly enhanced CB1R-dependent ROS
production. Intriguingly, the authors of the same study also
demonstrated that CB2R stimulation led to the activation of
Rap1, concomitant with the amelioration of CB1R-induced
ROS formation in macrophages [69]. These findings therefore
highlight the potential opposing effects of CB1R and CB2R
activation in the modulation of ROS production in macro-
phages, and implicate a key role for Rap1 in regulating
ROS levels by the ECS in immune cells.
In addition, the ECS has also been reported to regulate the
activity of redox-sensitive transcription factors. For example,
CB2R-mediated protection against myocardial infarction in
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Figure 3. Summary of pathways implicated in the regulation of ROS production by the ECS. (a) Activation of CB1R and/or CB2R has been reported to either
stimulate and/or repress the activity of enzymes implicated in ROS generation as indicated. For example, cannabinoid receptor activation may act to suppress
cAMP-dependent activation of PKA thereby repressing the expression and/or activity of enzymes such as NADPH oxidase. Alternatively, cannabinoid receptor stimu-
lation can activate PKC isoforms and the downstream MEK/ERK signalling axis which have been implicated in upregulating NADPH oxidase activity. (b)
Endocannabinoids such as anandamide have also been shown to target the vanilloid receptor TRPV1. In this case, TRPV1 activation would promote an increase
in intracellular calcium signalling which in turn may impact on the expression/activity of ROS generating enzymes, for example through stimulating CAMKII activity.
In addition, elevated calcium levels may also promote an increase in ROS generation within mitochondria. (c,d ) Endocannabinoids such as anandamide may also
convey protective effects by inducing the expression of antioxidant enzymes such as catalase, superoxide dismutase and glutathione peroxidase through activation of
CB1R or PPAR receptors. (e) Following its uptake into cells, for example via transporters such as fatty acid binding protein (FABP) isoforms, endocannabinoids such as
anandamide may also directly impact upon mitochondrial ROS generation through targeting CB1R residing within these organelles.
rsob.royalsocietypublishing.org
Open
Biol.6:150276
5
 on July 4, 2016http://rsob.royalsocietypublishing.org/Downloaded from 
mice was shown to coincide with increased nuclear
translocation of the transcription factor Nrf-2 in the myocar-
dium, concomitant with the induction of its target
gene haem oxygenase-1, a key cellular antioxidant [110].
Notably, Nrf-2 functions to activate the antioxidant response
element transcriptional pathway, thereby controlling the
expression of genes whose protein products are involved
in the detoxification and elimination of reactive oxygen
intermediates [111].
Alternatively, cannabinoid ligands may act to alter cellu-
lar ROS production through controlling the production of
mitochondrial-derived ROS. For example, in hepatic stellate
cells, mitochondria were found to be the predominant
source of ROS generated in response to 2-AG stimulation
[112]. Furthermore, a recent study by Ma et al. [113] demon-
strated that treating hippocampal neurons and tissue with the
CB1R agonist ACEA increased the expression of CB1R
protein in the mitochondrial membrane. Notably, in this
same study, ACEA was shown to inhibit ROS generation
and attenuate Ca2þ-induced mitochondrial injury, effects
that were prevented by co-application of a cell permeant
CB1R antagonist (AM251), but not following co-treatment
with a cell impermeable CB1R blocker (haemopressin). There-
fore, it is possible that CB1R residing within mitochondria
may act to control the production of ROS by these organelles,
for example, by altering the expression and/or activity
of components of the mitochondrial electron-transport
chain, and/or by promoting changes in mitochondrial
membrane potential.
4.2. CB1R/CB2R-independent modulation of cellular
reactive oxygen species production
As well as conveying their biological effects through
activation of CB1R and/or CB2R, it is possible that endocan-
nabinoids may also regulate ROS levels by targeting
alternative receptors/ion channels such as TRPV1 or GPR55
[55,56]. Indeed, one study performed by Balenga et al. [114]
revealed that 2-AG-induced ROS production in neutrophils
was significantly diminished upon co-treatment with the
GPR55 activator lysophosphatylinositol (LPI). Endocannabi-
noids such as AEA are also known to mediate some of
their cellular responses by targeting the non-selective cation
channel TRPV1, whose activation has been linked to
increased ROS production [115–118]. Indeed, this may be
driven, at least in part, through the ability of TRPV1 stimu-
lation to trigger Ca2þ signalling which is functionally
coupled to ROS generating systems, in particular mitochon-
drial ROS production, as well as the upregulation of Nox5
activity following its phosphorylation by CAMKII, a
serine/threonine protein kinase activated in response to cal-
cium signals [119–121]. In addition, AEA has also been
reported to target the PPAR family of nuclear receptors
[54], whose activation is known to induce the expression of
antioxidant enzymes, including catalase and glutathione
peroxidase 3 [122,123].
It should be highlighted that some cannabinoid receptor
ligands may also convey more direct free radical scavenging
activity. For example, analysis performed in cell-free bio-
chemical assays has revealed that some phenolic
cannabinoid compounds (e.g. D9-THC, cannabinol, cannabi-
diol, CP-55,940, HU-210 and AM-404) can act as potent
lipophilic antioxidants [124]. Moreover, owing to their
lipophilicity, these compounds may further affect mem-
brane-associated and intracellular signalling mechanisms,
leading to changes in the activity of membrane-bound recep-
tor systems (e.g. neurotransmitter receptors). Therefore,
such free radical scavenging activity should also be
considered as a potential explanation for non-CB1R/CB2R-
dependent modes of antioxidant action by cannabinoid
receptor ligands.
5. Redox-mediated regulation of the
endocannabinoid system
In addition to the effects of altering ECS activity upon cellular
redox homeostasis, it should be highlighted that changes in
cellular redox homeostasis can also impact upon the function
of the ECS. For example, activation of NADPH oxidase iso-
forms Nox4 and Nox1 has been reported to mediate the
upregulation of CB1R expression in mouse hepatic stellate
cells during Schistosoma J. infection [125]. Consistent with
this finding, H2O2-induced oxidative stress has been reported
to increase CB1R and CB2R mRNA and protein abundance in
human retinal pigment epithelial (RPE) cells, as well as
downregulating expression of FAAH, the enzyme involved
in the degradation of anandamide [126]. The authors of the
same study also demonstrated that treatment with the
CB2R agonist JWH-015 protected RPE cells from oxidative
damage, suggesting that upregulation of cannabinoid recep-
tor expression and/or endocannabinoid levels may
constitute part of a counter-feedback mechanism to amelio-
rate the damaging effects of ROS exposure under those
conditions. Furthermore, Batkai et al. [66] have reported elev-
ated hepatic levels of AEA and 2-AG following I/R injury
in mice. Notably, the authors of the same study also
demonstrated raised levels of these endocannabinoids in
hepatocytes following brief exposure to pro-oxidants (hydro-
gen peroxide and peroxynitrite). Therefore, these findings
support an important role for ROS in modulating ECS
function, for example by regulating the expression of key
ECS components.
6. Conclusion and future perspective
To conclude, there is growing appreciation that the ECS may
play an important role in the regulation of cellular redox
homeostasis. Collectively, the evidence presented in this
review indicates that ECS activation or inhibition can
convey detrimental and/or beneficial biological effects
through altering cellular ROS levels, depending on the cell
type and/or stimulus involved. Indeed, the studies high-
lighted in this review show that ECS function can impact
upon free radical production in a number of different ways
(figure 3). Crucially, given the importance of redox status
in the development of numerous pathologies, these findings
identify ECS components as potential therapeutic targets
for the treatment of oxidative stress-related neurological,
cardiovascular and metabolic disorders.
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